文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗成人特应性皮炎的真实世界法国多中心队列研究

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
PubMed 文献 · J Am Acad Dermatol · 2019-02-27

该研究为法国多中心回顾性真实世界队列,纳入2017年3月至2018年4月接受度普利尤单抗治疗的241例成人特应性皮炎患者。结果显示疗效与临床试验相似,但结膜炎和嗜酸性粒细胞增多的发生率较高。

要点

  • 度普利尤单抗真实世界疗效与临床试验相似。
  • 结膜炎发生率较高,达38.2%。
  • 随访期间嗜酸性粒细胞增多比例高于基线。

核心结论

  • 真实世界研究显示度普利尤单抗疗效与临床试验相似,但结膜炎和嗜酸性粒细胞增多发生率更高。

研究设计与样本

  • 法国多中心回顾性真实世界队列,纳入2017年3月至2018年4月接受度普利尤单抗治疗的241例成人特应性皮炎患者。

主要发现

  • SCORAD较基线改善≥75%的患者为27/163(16.6%),EASI较基线改善≥75%的患者为40/82(48.8%)。
  • 3个月时SCORAD中位数±IQR为25±21,低于基线的56±27.4(P<10^-9)。
  • 3个月时EASI中位数±IQR为4.1±6.8,低于基线的17.9±15.4(P<10^-9)。
  • 结膜炎发生率为84/241(38.2%)。
  • 随访期间嗜酸性粒细胞>500 cells/mm3的比例为57%,高于基线的33.7%(n=172,P<10^-6)。

临床怎么用

  • 真实世界应用中需关注结膜炎和嗜酸性粒细胞增多,并监测相关指标。

局限性

  • 无对照组。
  • 存在数据缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10-9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10-9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10-6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. LIMITATIONS: No control group, missing data. CONCLUSION: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019. PMID: 30825533. doi:10.1016/j.jaad.2019.02.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。